Drugs in development · updated 30 October 2026
Anemia: drugs in development
As of 30 October 2026 there are 65 active clinical trials (recruiting or ongoing, phases I–III) on 52 drugs for anemia. 21 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Elritercept | III | 4 | NCT06499285 |
| RoxadustatEvrenzo® | III | 3 | NCT05970172 |
| AND017 | III | 2 | NCT07494409 |
| MonoferIron Isomaltoside 1000 | III | 2 | NCT06884280 |
| BCD-131 | III | 1 | NCT07119372 |
| CholineCholine Bitartrate | II–III | 1 | NCT06527391 |
| Etavopivat | III | 1 | NCT04624659 |
| DISC-0974 | I–II | 2 | NCT05320198 |
| Anumigilimab | II | 1 | NCT07224360 |
| EDIT-301 | I–II | 1 | NCT04853576 |
| HS-20106 | II | 1 | NCT06594965 |
| LY-M001 | I–II | 1 | NCT06818838 |
| Ofirnoflast | II | 1 | NCT07738510 |
| RP-L102 | II | 1 | NCT04248439 |
| SAL-0951 | II | 1 | NCT06737081 |
| Senicapoc | II | 1 | NCT07282210 |
| Tebapivat | II | 1 | NCT05490446 |
| APG-5918 | I | 1 | NCT05773586 |
| MNV-201 | I | 1 | NCT06465160 |
| PMD-026 | I | 1 | NCT07379125 |
| Iron | Early I | 1 | NCT07577817 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| LuspaterceptACE-536, Reblozyl | III | 12 | NCT04717414 |
| Epoetin AlfaEprex, Epoetin alga | III | 4 | NCT07422480 |
| Iron sucroseVenofer | III | 3 | NCT03893045 |
| MitapivatAG-348, Pyrukynd® | III | 3 | NCT05144256 |
| Darbepoetin AlfaDarbeopoetin, Darbepoetin | III | 2 | NCT07300111 |
| Ferric derisomaltoseMonoferric® | III | 2 | NCT05407987 |
| Ferrous Sulfate | III | 2 | NCT06884280 |
| FerumoxytolFerabright®, Feraheme® | III | 2 | NCT03893045 |
| FludarabineFludara, FLUDARABIN | III | 2 | NCT02048813 |
| IptacopanLNP023, Fabhalta® | III | 2 | NCT06934967 |
| PacritinibVonjo® | III | 2 | NCT03165734 |
| RituximabRuxience, Rituxan | III | 2 | NCT02048813 |
| AzacitidineAzacytidine, 5-azacytidine | II–III | 1 | NCT05469737 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 1 | NCT02048813 |
| DaprodustatJesduvroq® | III | 1 | NCT07300111 |
Sorted by most advanced phase and number of active trials. Showing 15 of 31 drugs.
All 52 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Sickle-cell disease 73 drugs
- Aplastic anemia 43 drugs
- Paroxysmal nocturnal hemoglobinuria 36 drugs
- Beta thalassemia 34 drugs
- Myelodysplastic Syndromes 203 drugs
- Refractory anemia with excess of blasts 35 drugs
- Thalassemia 21 drugs
- Acute myeloid leukemia 314 drugs
- Autoimmune hemolytic anemia 13 drugs
- Hemoglobinopathies 22 drugs
- Chronic myelomonocytic leukemia 90 drugs
- Bone marrow failure 26 drugs
Broader categories
- Hematologic Diseases 57 drugs
- Bone marrow disease 14 drugs
- Nutritional and metabolic diseases 5 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Metabolic disease 30 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000740 “Anemia”.